KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Net Cash Flow (2017 - 2025)

Twist Bioscience (TWST) has disclosed Net Cash Flow for 7 consecutive years, with -$22.5 million as the latest value for Q3 2023.

  • On a quarterly basis, Net Cash Flow fell 916.73% to -$22.5 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$91.0 million, a 4.81% decrease, with the full-year FY2025 number at -$43.8 million, up 27.25% from a year prior.
  • Net Cash Flow was -$22.5 million for Q3 2023 at Twist Bioscience, down from -$5.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $256.1 million in Q4 2020 to a low of -$274.2 million in Q4 2021.
  • A 5-year average of $11.7 million and a median of -$5.4 million in 2023 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 1352.04% in 2020, then tumbled 916.73% in 2023.
  • Twist Bioscience's Net Cash Flow stood at -$20.5 million in 2019, then surged by 1352.04% to $256.1 million in 2020, then tumbled by 207.1% to -$274.2 million in 2021, then skyrocketed by 77.6% to -$61.4 million in 2022, then surged by 63.36% to -$22.5 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Net Cash Flow are -$22.5 million (Q3 2023), -$5.4 million (Q2 2023), and -$1.6 million (Q1 2023).